SCHEMBL841097

SCHEMBL841097

COCCOCCOCCOCCOCCOCCOCCCCCCOc1ccc(O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR5A1 Q13285 1/20 0.62
LTA4H P09960 4/20 0.54
APP P05067 1/20 0.49
KDM4E B2RXH2 1/20 0.45
RECQL P46063 1/20 0.45
GAA P10253 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
DRD3 P35462 1/20 0.44
RARB P10826 1/20 0.42
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
MAPK1 P28482 1/20 0.42
CASP1 P29466 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
SLCO1B3 Q9NPD5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL842057 0.91 APP (0.57) NR5A1LTA4HAPPKDM4ERECQL
SCHEMBL1478767 0.91 APP (0.57) NR5A1LTA4HAPPKDM4ERECQL
SCHEMBL16305613 0.91 APP (0.57) NR5A1LTA4HAPPKDM4ERECQL
SCHEMBL22383656 0.89 NR5A1 (0.71) NR5A1LTA4HKDM4EGAADRD2
SCHEMBL26246272 0.89 NR5A1 (0.71) NR5A1LTA4HKDM4EGAADRD2
SCHEMBL21578058 0.89 NR5A1 (0.71) NR5A1LTA4HKDM4EGAADRD2
SCHEMBL11601640 0.87 NR5A1 (0.68) NR5A1LTA4HAPPKDM4EGAA
SCHEMBL16305604 0.86 APP (0.53) NR5A1LTA4HAPPKDM4ERECQL
SCHEMBL77538 0.85 LTA4H (0.59) NR5A1LTA4HAPPDRD2DRD4
SCHEMBL10357881 0.84 NR5A1 (0.83) NR5A1LTA4HAPPGAARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651163-B1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LTD (IN) 2015-03-04 EP disclosed
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-8143366-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2012-03-27 US disclosed
US-20100216714-A1 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF JAMES KENNETH D 2010-08-26 US disclosed
US-20100216714-A1 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF JAMES KENNETH D 2010-08-26 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-20100081782-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME EKWURIBE NNOCHIRI N 2010-04-01 US disclosed
US-7662773-B2 which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure BIOCON LIMITED (IN) 2010-02-16 US disclosed
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LIMITED (IN) 2008-06-19 US disclosed
EP-1651163-A4 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME BIOCON LTD (IN) 2008-03-26 EP disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed
US-7335751-B2 Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2008-02-26 US disclosed
US-20060167234-A1 Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same BIOCON LIMITED (IN) 2006-07-27 US disclosed
WO-2006076471-A2 BNP CONJUGATES AND METHODS OF USE NOBEX CORPORATION (US) 2006-07-20 WO disclosed
EP-1651163-A2 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME Nobex Corporation (US) 2006-05-03 EP disclosed
WO-2005116655-A2 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF NOBEX CORPORATION (US) 2005-12-08 WO disclosed
WO-2005016240-A2 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME NOBEX CORPORATION (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216714-A1 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF NPR1, NPPA, NPR3 NR5A1 2080/4885LTA4H 1225/4885APP 1347/4885
US-20060167234-A1 Aryl carbamate oligomers for hydroilyzable prodrugs and prodrugs comprising same ALK, OGFR, AOX1 NR5A1 3682/4885LTA4H 606/4885APP 3570/4885
US-20080146778-A1 ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME ALK, AOX1, OGFR NR5A1 3633/4885LTA4H 505/4885APP 2774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.